comparemela.com

Page 8 - Y Mabs Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Y-mAbs Therapeutics (YMAB) Outperform Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research report released on Monday morning, RTT News reports. They currently have a $18.00 price objective on the stock, up from their prior price objective of $12.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.19) […]

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Receives $11 71 Average Price Target from Brokerages

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Receives $11 71 Average Price Target from Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 2 8% Higher

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) were up 2.8% on Tuesday . The company traded as high as $12.50 and last traded at $12.45. Approximately 32,320 shares changed hands during trading, a decline of 92% from the average daily volume of 411,775 shares. The stock had previously closed at $12.11. Analysts […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.